# Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

> **NCT02210871** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 44 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2
- Hepatic Impaired

## Interventions

- **DRUG:** semaglutide

## Key facts

- **NCT ID:** NCT02210871
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-07
- **Primary completion:** 2015-06-03
- **Final completion:** 2015-06-03
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2017-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02210871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02210871, "Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02210871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*